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atrix Metalloproteinase-9 Contributes to
uman Atrial Remodeling During Atrial Fibrillation
ukiko Nakano, MD,* Shumpei Niida, PHD,† Keigo Dote, MD,‡ Sou Takenaka, MD,*
idekazu Hirao, MD,* Fumiharu Miura, MD,* Mari Ishida, MD,* Tetsuji Shingu, MD,*
aijiro Sueda, MD,§ Masao Yoshizumi, MD, Kazuaki Chayama, MD*
iroshima and Nagoya, Japan
OBJECTIVES The purpose of this study was to determine the relationship between matrix metalloprotein-
ases (MMPs)-1, -2, and -9, and tissue inhibitors of metalloproteinases (TIMP)-1 and the
atrial structural remodeling during atrial fibrillation (AF).
BACKGROUND Matrix metalloproteinases, a family of proteolytic enzymes and TIMPs, regulate the
extracellular matrix turnover in cardiac tissue.
METHODS Tissue samples were obtained from 25 patients without a history of AF (regular sinus rhythm
[RSR]) and 13 patients with AF (paroxysmal AF: 6, chronic AF 7) undergoing cardiac
operations. We performed a western blotting analysis of the MMP-1, -2, and -9, and
quantitatively analyzed the expression of the MMP-9 and TIMP-1 by real time polymerase
chain reaction and ELISA. The localization of the MMP-9 was investigated by in situ
zymography and immunohistochemistry.
RESULTS The active form of the MMP-9 was significantly increased in the AF group in comparison
to that in the RSR group (p  0.05), but there were no differences between the groups in the
protein level of the latent form of the MMP-9 and active and latent forms of the MMP-1 and
MMP-2. We also demonstrated that the expression of the MMP-9 was significantly more
increased in the atria of the AF group than in that of the RSR group for both the messenger
ribonucleic acid (mRNA) (AF: RSR; 1: 1.5) and protein levels (AF: RSR; 3.9  1.3 : 1.5  0.4
ng/mg atrium). The expression level of the MMP-9 was also higher in the PAF group than in the
RSR group, however, the diameter of the left atrium was similar in both groups. The gelatinase
activity and left atrium diameter were positively correlated (p  0.05, R  0.766). The relative
expression of the mRNA for the monocyte chemoattractant protein-1 was higher in the AF group
than in the RSR group. Immunohistochemical analysis revealed that the MMP-9 was distributed
within the perivascular area and under the epicardium of the atria.
CONCLUSIONS We clearly showed that the expression of the MMP-9 increased in fibrillating atrial tissue,
which may have contributed to the atrial structural remodeling and atrial dilatation during
AF. (J Am Coll Cardiol 2004;43:818–25) © 2004 by the American College of Cardiology
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dtrial fibrillation (AF) is the most common arrhythmia (1)
nd is well known as a source of thromboembolic events (2).
he longer the duration of AF, the more persistent it
ecomes because of atrial remodeling. A shortening of the
trial refractory period, termed “electrical remodeling” (3–
), occurs first. Then, contractile remodeling, meaning a
ecrease in the atrial contractility, occurs, followed by
tructural remodeling, which guarantees the persistence of
F (8,9). Several reports have demonstrated that electrical
emodeling was caused by a reduction in the L-type Ca2
hannels and various kinds of potassium channels in atria
From the *Department of Medicine and Molecular Science, Graduate School of
iomedical Science, Hiroshima University, Hiroshima, Japan; †Department of
eriatric Research, National Institute for Longevity Science (NILS), Nagoya, Japan;
Department of Cardiology, Hiroshima City Asa Hospital, Hiroshima, Japan;
Department of Surgery, Hiroshima Graduate School of Medicine, Graduate School
f Biomedical Science, Hiroshima University, Hiroshima, Japan; and Department of
ardiovascular Physiology and Medicine, Graduate School of Biomedical Science,
iroshima University, Hiroshima, Japan. This work was supported by the Tsuchiya
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Manuscript received July 2, 2003; revised manuscript received July 28, 2003,pccepted August 5, 2003.ith AF (10–13). However, both the mechanism and the
ole of the structural remodeling of AF still remain unclear.
emodeling of cellular ultrastructures, such as myolysis
ccurring in the atrial myocardium, is known to develop
rogressively during AF (14). An increase in the expression
f the gap junctions (connexin 40) has been reported to
nduce changes in the biophysical properties of the atrial
issue during AF (15,16). Enhanced disintegrin and metal-
oproteinase (ADAM) activity was also reported to be a
olecular mechanism contributing to the dilation of fibril-
ating human atria (17).
Matrix metalloproteinases (MMPs) are a family of
roteolytic enzymes, and they regulate the extracellular
atrix turnover in a balance with the tissue inhibitors of
etalloproteinases (TIMPs) (18,19). The extracellular
atrix degradation by MMPs has been known to be
ssociated with the pathogenesis of cardiovascular dis-
ases, including atherosclerosis, restenosis, dilated car-
iomyopathy, and myocardial infarction (MI) (20,21). In
articular, many reports have demonstrated that MMP-9
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March 3, 2004:818–25 Matrix Metalloproteinases and Atrial Remodelinglays an important role in ischemia-reperfusion–induced
yocardial matrix remodeling and could be a target for
he prevention or treatment of acute ischemic myocardial
njury (19,21–25).
The purpose of this study was to investigate the role of
MP-1, -2, and -9 and TIMP-1 in AF-induced human
trial remodeling.
ETHODS
issue collection. Right atrial appendages were obtained
rom 38 patients undergoing cardiac operations, which
onsisted of 25 patients with regular sinus rhythm (RSR)
ithout a history of AF, and 13 patients with AF (parox-
smal AF [PAF]: 6 patients; chronic AF [CAF]: 7 pa-
ients). The institutional ethics committee of the Graduate
chool of Biomedical Science, Hiroshima University, ap-
roved all procedures involving human tissue usage. In-
ormed consent was obtained from patients before tissue
arvesting. A transverse section (5 to 8 mm) of the atrial
ppendage was divided into three sections. One was em-
edded in an OCT compound (Sakura, Torrance, Califor-
ia) and frozen with liquid nitrogen. The tissue blocks were
tored at 80°C until sectioning. Another section was
uickly frozen with liquid nitrogen and stored at 80°C
ntil the protein would be extracted. The other section was
reserved in RNAlater (Ambion, Austin, Texas) at 4°C and
sed to extract the RNA.
LISA and Western blotting analysis. Frozen cardiac
amples were homogenized in a lysis buffer (20 mmol/l Tris;
% Triton X; 10% glycerol; 1% DOC; 0.1% SDS; 50
mol/l NaF; 10 mmol/l NaP2O4; 1 mmol/l DTT; 1
mol/l Banadate; 10 g/ml leupeptin, pH 7.4) with a
ilconia bead at 30 frequency/s and 4°C for 8 min using an
M 300 (Quagen, Hilden, Germany) and centrifuged at
4,000 rpm at 4°C for 10 min. The protein concentrations
f the supernatants were determined by DC protein assay
Bio-Rad, Richmond, California). Equal amounts of the
roteins were assayed for human MMP-9 and TIMP-1
roduction by ELISA kits purchased from R&D Systems
Minneapolis, Minnesota) according to the manufacturer’s
nstructions. All assays were performed in duplicate.
The same samples used for the ELISA assay of the
MP-9 were also used for the Western blot analysis of the
Abbreviations and Acronyms
AF  atrial fibrillation
ADAM  A Disintegrin And Metalloproteinase
MCP-1  monocyte chemoattractant protein-1
MMPs  matrix metalloproteinases
PAF  paroxysmal AF
RSR  regular sinus rhythm
RT-PCR  reverse transcription-polymerase chain
reaction
TIMPs  tissue inhibitors of metalloproteinasesMP-1, -2, and -9. Equal amounts of protein (2 g) were Xeparated by SDS–PAGE and immunoblotted to a nitro-
ellulose membrane with anti-MMP antibodies (Oncogene
esearch Products, San Diego, California), which recog-
ized their latent or active forms. The MMP protein bands
ere visualized using HRP-conjugated anti-IgG secondary
ntibodies and ECL plus Western blotting detection re-
gents (Amersham Biosciences, Buckinghamshire, UK).
he membranes were washed, dried, and exposed to X-ray
lm (Kodak). The images were analyzed with National
nstitutes of Health (NIH) images and quantified by nor-
alizing them with that from beta-actin.
uantitative reverse transcription-polymerase chain re-
ction (RT-PCR). Tissue samples taken from the RNA-
ater (Ambion, Austin, Texas) were pulverized in Trizol
eagents (1 ml/100 mg tissue), and the total RNA was
xtracted by the Trizol method supplied by Invitrogen.
recisely 1 g of the total RNA from each sample was
everse-transcribed to generate complementary deoxyribo-
ucleic acid (cDNA) using Ready-To-Go RT-PCR beads
Amersham Pharmacia, Piscataway, New Jersey) and the
andom primer pd (N)6. This mixture was placed in a
hermal cycler (model 9600) at 42°C for 20 min and 95°C
or 5 min. Quantitative PCR was performed using a Light
ycler (Roche, Mannheim, Germany). The cDNA (10 l
ach) was diluted to a volume of 20 ml with a PCR mixture
Light Cycler Fast Start DNA Master SYBR Green I kit
Roche]) containing 0.5 mol of specific primers (Light
ycle Primer Set) for the MMP-9, TIMP-1, monocyte
hemoattractant proteins (MCP-1), and tumor necrosis
actor-alpha (TNF-). Initial denaturation at 95°C for 10 m
as followed by amplification, involving 35 cycles with
enaturation at 95°C for 10 m, annealing at 68°C for 10 s
nd elongation at 72°C for 16 s. All samples were analyzed
n triplicate. The fluorescence intensity of the SYBR Green
reflected the amount of PCR products actually formed.
ilm in situ zymography. In situ zymography using FIZ
lms was used to determine the localization of the MMP-2,
3, -7, and -9 activity. The FIZ films were coated with
elatin in either the presence (FIZ-GI film) or absence
FIZ-GN fi lm) of an MMP inhibitor (1,10-
henanthroline) (FUJIFILM, Japan). Unfixed frozen sec-
ions (6 m) were placed on the films and incubated for
4 h at 37°C with 100% humidity and stained with Biebrich
carlet. The MMP-2, -3, -7, and -9 activity was visualized
y both the loss of staining in the FIZ-GN films and
taining in the FIZ-GI films. Images of the FIZ-GN films
ere scanned, and the gelatinase activity was analyzed using
IH images.
mmunohistochemical staining of MMP-9 and CD11b.
e conducted double immunofluorescent staining for
MP-9 (Santa Cruz, California) and CD11b (macrophage
arker, Dako Japan, Kyoto). The nuclei were stained with
oechst 33342. Frozen sections of atrium were washed
ith PBS, fixed with 4% paraformaldehyde for 15 min at
oom temperature, and permeabilized with 0.5% Triton
-100/PBS for 5 min. After blocking with 1% BSA/PBS
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Matrix Metalloproteinases and Atrial Remodeling March 3, 2004:818–25nd incubating with primary antibodies in 1% BSA/PBS,
he sections were incubated with secondary antibodies
Alexa 488/568). Specimens were observed using confocal
aser scanning microscopy (Leica DM IRBE).
tatistical analysis. Clinical characteristics and quantita-
ive data were compared between the AF and RSR groups
y the Mann-Whitney U test. The Kruskal-Wallis test was
sed to compare the three groups (RSR, PAF, and CAF).
ata are presented as mean  SD. A p value  0.05 was
onsidered statistically significant.
ESULTS
o differences existed in the gender, age, or percentage of
ral administration with angiotensin-converting enzyme
ACE) inhibitors, angiotensin I receptor blockers, diuretics,
nd beta-blockers between the AF and RSR groups. From
he cardiac echocardiography, the left ventricular (LV)
unction and LV mass were similar among the AF and RSR
roups (Table 1). The left atrial diameter was similar in the
SR and PAF groups, but larger in the CAF group than in
he RSR group (35.7  6.1 mm in the RSR group, 40.2 
.8 mm in the PAF group, and 51.8 10.5 mm in the CAF
roup, p  0.05).
As a result of Western blotting analysis, the active form of
he MMP-9 (88 kDa) was significantly increased in the AF
roup in comparison to that in the RSR group (p  0.05),
ut no difference existed in the protein level of the latent
orm (92 kDa) of the MMP-9 and active and latent forms
able 1. LV Function and LV Mass Among AF and RSR
roups
AF
(n  13)
RSR
(n  25)
ender (male/female) 10/3 20/5
ge (yrs) 68  9 65  12
chocardiography
LAD (mm) 50.6  9.2* 35.7  6.1
IVSTd (mm) 11.2  2.5 10.8  2.4
LVDd (mm) 52.8  9.5 48.2  7.5
EF (%) 58.1  5.0 61.3  16.9
edication
ACE inhibitor (%) 23 8
ARB (%) 8 4
Digoxin (%) 62* 8
Diuretics (%) 38 32
Beta-blocker (%) 15 12
Ca-blocker (%) 15* 60
Nitrate (%) 8* 56
peration (%)
CABG 8 77
Valve (A/M/T) 54 (8/61/15) 23 (8/12/4)
Thrombotectomy 54 0
Maze 31 0
p  0.05, atrial fibrillation vs. regular sinus rhythm.
A  aortic valve; AF  atrial fibrillation; ARB  angiotensin II receptor blocker;
F  ejection fraction; IVSTd  interventricular septum thickness; LAD  left
trial diameter; LV  left ventricular; LVDd  left ventricle diastolic diameter; M 
itral valve; RSR regular sinus rhythm; T tricuspid valve; Thrombectomy left
trial or left atrial appendages thrombectomy; Valve (A/M/T) valve replacement or
lasty.f the MMP-1 (43 and 55 kDa, respectively) and MMP-2 i66 and 72 kDa, respectively) between the two groups (Fig.
). Also, the ELISA analysis showed that the protein level
f the MMP-9 was significantly increased in the AF group
igure 1. Results of the measurement of the matrix metalloproteinase
MMP)-1, -2, and -9 using the Western blotting analysis. The active form
f MMP-9 (88 kDa) significantly increased in the atrial fibrillation (AF)
roup in comparison to that in the regular sinus rhythm (RSR) group (p 
.05), but there was no difference in the protein level of the latent form of
MP-9 (92 kDa) (top panel). No difference existed in the protein level of
he active and latent forms of the MMP-1 (middle panel) and MMP-2
bottom panel) between the two groups. Closed bars  AF group; open
ars  RSR group. *p  0.05, AF vs. RSR.n comparison to that in the RSR group (Fig. 2A, p 0.05).
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March 3, 2004:818–25 Matrix Metalloproteinases and Atrial Remodelinghe TIMP-1 protein showed a tendency to rise in the AF
atients as compared to that in the RSR patients, but it was
ot significant (p  0.1, Fig. 2A). Interestingly, the expres-
ion level of the MMP-9 was also higher in the PAF group
han in the RSR group (RSR: PAF, p 0.05, Fig. 2B). The
evel of the TIMP-1 protein was positively correlated to the
eft atrial diameter (p  0.05, R  0.453).
The relative expression of the MMP-9 mRNA was
igher in the AF group than in the RSR group (Fig. 3A, p
0.05). The difference in the expression of the TIMP-1
RNA between the two groups was not significant. The
atio of the MMP-9 to TIMP-1 was higher in the AF
roup than that in the RSR group (p 0.05). Expression of
he MCP-1 mRNA was higher in the AF group than in the
SR group, whereas that of the TNF- mRNA was similar
etween the groups (Fig. 3B).
Hematoxylin-eosin staining showed that, in the atrium,
he cell layer under the epicardium was thicker in the AF
roup than in the RSR group (Figs. 4A and 4B). In situ
ymography revealed that the activity of the gelatinase,
epresented as unstained spots with Biebrich scarlet in the
IZ-GN films, was higher in patients with AF than in
hose with RSR (Figs. 4C and 4D). The unstained spots in
he FIZ-GN films completely disappeared in the MMP
igure 2. Expression level of the MMP-9 protein and tissue inhibitors of
etalloproteinase (TIMP)-1 protein by enzyme-linked immunosorbent
ssay. (A) The expression level of the MMP-9 protein was also higher in
he AF group (closed bar) than in the RSR group (open bar) (p  0.05),
nd the TIMP-1 protein showed a tendency to rise in the AF patients as
ompared to that in the RSR patients (p  0.1). (B) Comparison of the
xpression of the MMP-9 protein among the three groups. The expression
evel of MMP-9 was higher not only in the CAF group, but also in the
aroxysmal atrial fibrillation (Paf) group, than that in the RSR group.
losed bars  AF group; open bars  RSR group. *p  0.05, AF vs.
SR. Abbreviations as in Figure 1.nhibitor-coated FIZ-GI films, meaning that all the spots seflected the activity of the MMP (gelatinase) (Figs. 4E and
D). The activity of the gelatinase was distributed under the
picardium, in the lumens of blood vessels, and in the
nterstitium of cardiac myocytes. Gelatinase activity was
igher in the AF group than in the RSR group (13.1 
.3% vs. 7.3 2.3%). The left atrial diameter and gelatinase
ctivity were positively correlated (Fig. 5, p  0.05, R 
.766).
Immunohistochemical analysis showed that, in the atria
ith AF, the MMP-9 was found mainly in the perivascular
rea, under the epicardium, and sporadically in the intersti-
ium of the cardiomyocytes (Figs. 6A and 6B). Conversely,
n the atria with RSR, we could not detect any MMP-9 in
he perivascular area, and there were thin layers of the
MP-9 under the epicardium. The staining of the MMP-9
ppeared as fibers in the enlarged view (Fig. 6C). In the
ame place, we observed collagen fibers stained blue with
asson trichrome (Fig. 6D). The double staining of the
MP-9 and CD11b revealed that the distribution of the
MP-9 was not always coincident with that of the CD11b
Fig. 7).
ISCUSSION
trial fibrillation is a common arrhythmia (1) and, unfor-
unately, a potential source of thromboembolic events (2).
s AF has a tendency to become persistent due to atrial
emodeling, new strategies for early termination of AF
igure 3. Relative expression of messenger ribonucleic acid (mRNA) from
MP-9, TIMP-1, monocyte chemoattractant protein (MCP)-1, and
umor necrosis factor (TNF-). (A) The relative expression of mRNA
rom MMP-9 was higher in the AF group than in the RSR group. (B) The
elative expression of mRNA from MCP-1 was higher in the AF group
han in the RSR group and that of the TNF- was similar in the two
roups. Closed bars AF group; open bars RSR group. *p 0.05, AF
s. RSR. Abbreviations as in Figure 1hould be established by clarifying the mechanisms of the
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Matrix Metalloproteinases and Atrial Remodeling March 3, 2004:818–25trial remodeling induced by AF. Many investigators have
emonstrated that changes in the electrophysiological prop-
rties occur during AF, and ionic channel remodeling
actors, such as a reduction in the L-type Ca2 channels and
ownregulation of several kinds of potassium channels, have
een represented as probable explanations for these changes
10–13). Some researchers have shown that the expression
f gap junctions (connexin 40) increased in the atria during
F (15,16). Recently, it was reported that ADAM activity
ncreased in fibrillating human atria (17). These changes in
he expression of gap junctions and ADAMs cause struc-
ural changes in the atrium that are considered to be part of
he pathogenesis of sustained AF. However, there still has
een little information about the mechanisms of structural
emodeling in the atria with AF.
Matrix metalloproteinases are a family of proteolytic
igure 4. Hematoxylin-eosin staining and in situ zymography in atria with
picardium of the atrium was thicker with AF (A) than with RSR (B). In s
pots from the Biebrich scarlet in the FIZ-GN films, was higher in patients
y an MMP inhibitor, which presented as unstained spots in the FIZ-GN fi
200. Abbreviations as in Figure 1.nzymes that regulate the extracellular matrix turnoverogether with the inhibitory mediators of the MMPs called
IMPs (18,19). The MMPs have been known to be
nvolved in the pathogenesis of many kinds of cardiovascular
iseases, including atherosclerosis, restenosis, dilated car-
iomyopathy, and MI (20,21). The MMP-1, -2, -3, -9,
13, and -14 exist in the mammalian myocardium. It has
lso been reported that MMP-9 especially plays a pivotal
ole in myocardial remodeling in ischemic cardiomyopathy
nd chronic heart failure (19, 21–25). We selected MMP-1,
2, and -9 to investigate the mechanism of the atrial
emodeling by AF in the present study. In addition,
ompared to the vast information on ventricular myocardial
emodeling, there has been little information as to whether
r not the MMPs exist in human atrial tissue, and certainly
here has been no data on the relationship between the
MPs and the atrial remodeling in AF.
and AF. Hematoxylin-eosin staining showed that the cell layer under the
mography showed that the activity of gelatinase, represented as unstained
AF (C) than in those with RSR (D). The activity was completely blocked
) and which disappeared in the FIZ-GI films (F). Original magnification:RSR
itu zy
with
lms (EIn this study, we first investigated whether or not the
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March 3, 2004:818–25 Matrix Metalloproteinases and Atrial Remodelingxpression of MMP-1, -2, and -9 differed between human
tria with AF and with RSR. As a result of Western blotting
nalysis, the active form of MMP-9 was significantly
ncreased in the AF subjects in comparison to those in the
SR group (p  0.05), but no difference was observed in
he protein level of the latent form of the MMP-9 and
ctive and latent forms of the MMP-1 and MMP-2
etween the two groups of subjects. Also, the ELISA
nalysis showed that expression of the MMP-9 in the atria
ncreased step by step, as the rhythm changed from RSR to
igure 5. Relationship between the gelatinase activity and left atrial (LA)
iameter. The level of gelatinase activity was positively correlated to the left
trial diameter. (p  0.05, R  0.766).
igure 6. Immunohistochemical analysis of the atria. Immunohistochem
erivascular region (A), under the epicardium (B), and sporadically in the
n the enlarged view (C). In the same region, collagen fibers are stained b400. Abbreviations as in Figure 1.AF and from PAF to CAF. As for the TIMP-1, the level
f the TIMP-1 protein was positively correlated to the left
trial diameter. The positive correlation between the left
trial diameter and the expression of the TIMP-1 protein
uggested that the TIMP-1 protein increased in compen-
ation for the MMP-9 increase. We also demonstrated that
he expression of the MMP-9 was more increased in the
tria of the AF group than in that of the RSR group, not
nly for the protein level, but also the mRNA level. Based
n these data, the MMP-9 was judged to be a strong
andidate for being associated with the atrial structural
emodeling during AF. As the MMP-9 overexpressed, the
IMP-1 compensatingly increased, but it did not catch up
o the MMP-9 increase, and the balance between them
roke down, thus possibly resulting in the atrial structural
emodeling of AF.
We first demonstrated the existence and distribution of
he MMP-9 in the atrial tissue in the present study. In the
tria with AF, the MMP-9 exists mainly in the perivascular
rea, under the epicardium, and sporadically in the intersti-
ium of cardiomyocytes, whereas in the atria with RSR, it
as found only under the epicardium as a thin layer and
arely in the interstitium. The staining of the MMP-9
ppeared as fibers, and the image reflected the secreted
MP-9 ridden of collagen fibers.
The MMP-9 is usually found in human and ventricular
nalysis showed that in atria with AF, the MMP-9 exists mainly in the
titium of cardiomyocites. The staining of the MMP-9 appeared as fibers
th Masson trichrome (D). Original magnification: A, B 200 and C, Dical a
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Matrix Metalloproteinases and Atrial Remodeling March 3, 2004:818–25yocardial remodeling. It has been known to be associated
ith macrophages, infiltrating neutrophils, fibroblasts, and
ascular smooth muscle cells (26 –28). Inflammatory
hanges have been known to contribute to the atrial struc-
ural remodeling and to increase the propensity for AF to
ersist (29). Recently, investigators reported that inflamma-
ory cells indicative of chronic inflammation had infiltrated
he dilated atrium (30). Monocyte chemoattractant
rotein-1 is a type of chemokine, caused by changes in the
enin-angiotensin system and shear stress; it is an important
ediator in many pathologies recruited by multiple leuko-
ytes, and it is known to be closely related to MMPs (31).
n this study, the relative expression of the mRNA of the
CP-1, indicative of chronic inflammation, was higher in
he AF group than in the RSR group, but the TNF-,
ndicative of acute inflammation, was similar for both
roups. However, double staining of the MMP-9 and
ac-1 revealed that the distribution of the MMP-9 did not
lways coincide with that of the Mac-1, suggesting that the
MP-9 in atria with AF partially originates from blood
ells.
igure 7. Double staining of the matrix metalloproteinases (MMP)-9 and
D11b in the atria. The double staining of the MMP-9 and CD11b
evealed that the distribution of the MMP-9 was not always coincident
ith that of the CD11b. Original magnification: upper panel200; lower
anel 400.Expression of the MMP mRNA can be modulated byarious chemical agents, such as neurohormones, cortico-
teroids, and cytokines influencing the MMP gene expres-
ion through the formation of transcription factors binding
o specific response elements on the MMP gene promoters
21). The common response elements contained in the
romoter region of the MMP genes are known to be
ctivator protein-1 (AP-1) and NF-B sites (32). The
NF-, a cytokine, is known to be a contributor to LV
yocardial remodeling. Moreover, TNF- was reported as
ne of the molecular triggers for the induction of myocardial
MPs in LV remodeling (33). In our study, the relative
xpression of the TNF- was similar for both the atria with
F and those with RSR.
In the present study, we clarified that the expression of
he MMP-9 had increased in the fibrillating atria, but the
echanism of the MMP-9 increase is the subject of a
eparate study. The molecular mechanisms of AF were not
ompletely clarified in previous studies, but there was a
eport that an ACE-dependent increase in the amount of
ctivated extracellular signal-regulated kinases Erk1/Erk2 in
trial interstitial cells might spur on atrial fibrosis in atria
ith AF (34). Angiotensin II (Ang II) was reported to
ediate the upregulation of the matrix gelatinase (MMP-9)
nd to be related to the cardiac hypertrophy process and
ardiac remodeling (35). It was also reported that Ang II
lockade prevented myocardial fibrosis, and the long-term
ombined endothelin-A receptor and ACE inhibition im-
roved cardiac failure (36). Angiotensin II was reported to
e involved in the mechanism of the atrial electrical remod-
ling, and blockade of Ang II may lead to a better
herapeutic management of human AF (37). Hence, alter-
tions in the renin-angiotensin system in hearts with AF
ay be a possible trigger of the MMP secretion.
In conclusion, we clarified that the expression of the
MP-9 increased in the fibrillating atrial tissue, and the
lteration in the MMP-9/TIMP-1 may contribute to the
trial structural remodeling and atrial dilation during AF.
dditionally, we clarified that the distribution of the
MP-9 was in the perivascular area and under the epicar-
ium in the atria.
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